By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Northwest Biotherapeutics, Inc. 

21720 23rd Drive SE, Suite 100

Bothell  Washington  98021  U.S.A.
Phone: 425-608-3000-or-877-606-9246-Toll-Free Fax: 425-608-3026




Cytogen Corporation  Development of ex vivo prostate cancer immunotherapy

Company News
Northwest Biotherapeutics (NWBO) Reports Promising Survival Data In 51 Gbm Patients Treated With Dcvax-L 3/27/2015 7:24:57 AM
Northwest Biotherapeutics (NWBO) To Present At The 2nd Immunotherapy Of Cancer Conference, ITOC-2 3/24/2015 11:22:04 AM
Northwest Biotherapeutics (NWBO)'s Phase 3 Trial Of Dcvax-L For Gbm Brain Cancer Approved To Proceed In Canada And Under Way At Two Sites 2/19/2015 11:07:29 AM
Northwest Biotherapeutics (NWBO) To Present At 17th Annual BIO CEO & Investor Conference 2/9/2015 11:25:31 AM
Northwest Biotherapeutics (NWBO) To Present At The 7th Annual Phacilitate Immunotherapy Forum 1/23/2015 10:38:39 AM
Northwest Biotherapeutics (NWBO) To Present At Biotech Showcase Conference 1/8/2015 2:37:10 PM
Northwest Biotherapeutics (NWBO) Recaps 2014 Progress, Provides Dcvax-Direct Trial Update At Oppenheimer's 25th Annual Healthcare Conference 12/12/2014 8:11:48 AM
Northwest Biotherapeutics (NWBO) Reports $35M In Financing 11/20/2014 5:58:07 AM
Northwest Biotherapeutics (NWBO) Release: DCVAX®-L Hospital Exemption Program Now Under Way In Germany 10/14/2014 12:50:20 PM
Northwest Biotherapeutics (NWBO) Secures $11.5 Million Financing 10/7/2014 7:11:59 AM